- Sanofi India’s net income for the second quarter stands at 695 million rupees, a 33% drop compared to 1.03 billion rupees the previous year.
- Revenue decreased by 13% year-over-year, reaching 4.06 billion rupees, missing the estimated 5.04 billion rupees.
- Other income rose significantly by 81% year-over-year, amounting to 87 million rupees.
- Total costs were reduced by 10% compared to last year, totaling 3.21 billion rupees.
- Analyst recommendations include two buys, one hold, and one sell on Sanofi India.
A look at Sanofi Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts foresee a promising long-term outlook for Sanofi, the pharmaceutical giant known for manufacturing prescription drugs and vaccines. Based on the Smartkarma Smart Scores, Sanofi has received a commendable rating in several key areas. The company has been recognized for its solid dividend performance and resilience, scoring notably high. Additionally, its value and growth factors have been assessed favorably, indicating a stable position within the market. However, with a slightly lower score in momentum, Sanofi may face challenges in maintaining a strong upward trend in the near future. Despite this, the overall outlook points towards a company with a sound financial standing and growth potential.
Sanofi‘s diverse portfolio of cardiovascular, metabolic disorder, central nervous system, and oncology medicines has positioned it as a global player in the pharmaceutical industry. Serving customers worldwide, Sanofi continues to innovate and develop vital healthcare solutions. With a strategic focus on dividends and resilience, coupled with a strong value proposition and growth trajectory, Sanofi remains a key player to watch in the pharmaceutical sector. As the company navigates market dynamics and capitalizes on its strengths, investors may find Sanofi to be a compelling choice for long-term investment opportunities.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
